Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting a clinical study titled ‘A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Dose Topical Administration of PF-07905428 in Healthy Participants and Participants With Acne Vulgaris.’ The study aims to assess the safety and effectiveness of PF-07905428, a potential treatment for acne vulgaris, in participants aged 18 to 40. This research is significant as it explores new treatment avenues for a common skin condition.
The intervention being tested is a topical drug called PF-07905428, available in low (0.08%) and high (0.24%) strengths. It is designed to treat acne vulgaris by being applied daily to the face and/or back of participants.
The study follows an interventional design with randomized allocation and a parallel intervention model. It employs double masking, meaning both participants and investigators are unaware of who receives the actual drug versus a placebo. The primary purpose of the study is treatment-focused.
The study began on November 22, 2024, with an estimated completion date yet to be announced. The last update was submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
This study update could influence Pfizer’s stock performance by potentially boosting investor confidence if the drug proves effective. It also positions Pfizer competitively in the dermatological treatment market, where innovation is key.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.